BioCryst Pharmaceuticals Inc (BCRX)vsMerck & Company Inc (MRK)
BCRX
BioCryst Pharmaceuticals Inc
$8.12
-2.05%
HEALTHCARE · Cap: $2.25B
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 6977% more annual revenue ($66.57B vs $940.61M). MRK leads profitability with a 4.8% profit margin vs -40.9%. MRK appears more attractively valued with a PEG of 2.64. BCRX earns a higher WallStSmart Score of 55/100 (C-).
BCRX
Buy55
out of 100
Grade: C-
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BCRX.
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 45.1%
Revenue surging 33.6% year-over-year
Earnings expanding 1400.0% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Expensive relative to growth rate
ROE of -1925.0% — below average capital efficiency
Distress zone — elevated risk
Currently unprofitable
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : BCRX
The strongest argument for BCRX centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 33.6% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : BCRX
The primary concerns for BCRX are PEG Ratio, Return on Equity, Altman Z-Score.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
BCRX profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
BCRX carries more volatility with a beta of 0.56 — expect wider price swings.
BCRX is growing revenue faster at 33.6% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
BCRX scores higher overall (55/100 vs 36/100) and 33.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioCryst Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?